Uterine myomas are very common in women of repro-
ductive age and their diagnosis does not always require
surgery. With the introduction of GnRH analogs medical
treatment has become feasible. This medical treatment is
capable of inducing a substantial reduction in the volume of
the myoma (up to 50%) by reducing circulating oestrogen
levels. Maximum reduction is achieved by a twelve-week
therapy. However, after cessation of therapy, the myoma can
again increase its size, up to the initial diameter, within
three months. Myomas may be responsible for metrorrhagia,
pelvic pain, anaemia, infertility, and abortion. When these
symptoms occur, primary treatment might be analgesics for
pelvic pain, iron for anaemia, or even IVF for infertility.
However, if this treatment is unsuccessful, surgery is always
indicated